Translate page

× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Physicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("New Discussion" button below). Please include the country of origin.

Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM PHYSICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

cml therapy in hiv positive patients

  • jeff lipton
  • jeff lipton's Avatar Topic Author
9 years 1 month ago #1013 by jeff lipton
cml therapy in hiv positive patients was created by jeff lipton
Two similar cases for consideration.
1. 44 year old male with HIV diagnosed in 1988 on HAART (atazanavir 150mg/daily, emtricitabine/tenofavir 200/300mg/daily, ritonavir 100mg/daily) obviously quite successfully. Diagnosed in October 2014 with CML-CP, usual Ph-positive and bcr-abl positive. Started on imatinib at 400mg daily. Initially some very transient problems with cytopenias and cholestatic jaundice, now all resolved. Has CHR and about to be checked for 3-month molecular response. Has had significant drop in absolute CD4 and CD8 counts with no change in therapy.
2. 55 year old male with HIV diagnosed in 1993 on HAART (abacavir/lamivudine 600/300mg/daily, nevirapine 400mg/daily) again obviously quite successfully. In 2008 bcr-abl negative, JAK2 negative MPD. No therapy. In 2010 diagnosis of ITP treated with splenectomy. bcr-abl and JAK2 negative again in 2011. In 2014, worsening neutrophilia with left shift and now Ph-positive and bcr-abl positive. Stated on imatinib 400mg daily. Transient issue with cytopenia. Blood counts now stable. Stable 0.33%IS response at 6 and 9 months. Has had a less dramatic drop in absolute CD4 and CD8 counts.

The two questions open for discussion are:
1. Best choice of TKI in these cases
2. What should be the response to the drop in CD4 and CD8 counts.
  • Brian Druker
  • Brian Druker's Avatar Topic Author
9 years 1 week ago #1017 by Brian Druker
Replied by Brian Druker on topic cml therapy in hiv positive patients
Answer 1

Speaking with our HIV pharmacy specialist and we came to the following thoughts/insights

Imatinib – the most likely to interact via the CYP system and in both patients they would be at higher risk for hepatic toxicity and would need to be monitored more closely in that regard

Nilotinib – less risk for CYP interaction but at higher risk for Qtc interaction depending on the retroviral agents. Risk for metabolic issues, especially hyperlipidemias, and multiple of the combination HIV agents have a small incidence of pancreatitis which may be something to look more closely for.

Dasatinib – probably the least risk for QTC and CYP interactions, none of the current anti-HIV combos have problems with pulmonary side effects/effusions

Other thoughts
Regimens with zidovudine have increased risk for leukopenias and anemia up front
In all patients once the anti-CML TKI is chosen it would be worth getting an ID consult to see if there is a more modern HAART regimen that might be used as some of the newer HIV agents since as dolutegravir and raltegravir have lower drug interaction profiles and may be able to decrease the overall risk of toxicity as long as their virus is susceptible.

Joseph Bubalo (OHSU Pharmacy)

Answer 2

There is also a published series of six patients showing good outcomes with imatinib and HAART: Chronic myeloid leukemia and HIV-infection.
Schlaberg R, Fisher JG, Flamm MJ, Murty VV, Bhagat G, Alobeid B. Leuk Lymphoma. 2008 Jun;49(6):1155-60.

The limited data with imatinib suggests no change in lymphocytes counts: Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Rohon P, Porkka K, Mustjoki S. Eur J Haematol. 2010 Nov;85(5):387-98, but some patients, in an older article developed hypogammaglobulinemia: Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. Steegmann JL, Moreno G, Aláez C, Osorio S, Granda A, de la Cámara R, Arranz E, Reino FG, Salvanés FR, Fernández-Rañada JM, Muñoz C. Haematologica. 2003 Jul;88(7):762-8

Hope this helps.

Brian Druker
  • Michele Baccarani
  • Michele Baccarani's Avatar Topic Author
9 years 1 week ago #1018 by Michele Baccarani
Replied by Michele Baccarani on topic cml therapy in hiv positive patients
Patient no.1: To take a decision and to guide better treatment I think that it is necessary to monitor BCR-ABL transcript level and CD4 CD8 count with current drug doses. If the pt achieve an MMR, the dose of imatinib can be reduced, with further monitoring. If lymphocyte count drops more, imatinib can be discontinued for a period (one month?) to understand what happens to BCR-ABL and to lymphocyte count.

Patient no. 2: same as patient no. 1

In any case, it is not possible to advise if one does not know the data (BCR-ABL%, CD4 and CD8)) and the changes of the data over time.

Kind regards, Michele Baccarani
Moderators: Nicolaarlene